T-Cell Lymphoma Following CAR T-Cell Therapy

Occurrence of this second malignancy is rare, but awareness is essential for patients and the oncology care team.

Cellular immunotherapy with chimeric antigen receptor (CAR) T-cell products can provide durable responses in relapsed and refractory B-cell malignancies, but rare cases of T-cell malignancy among patients treated with CAR T have been identified. Two research groups examine this issue.

To assess the risk of second primary malignancies in recipients of CAR-T therapy, investigators with partial industry support conducted a single-institution retrospective analysis. Since 2016, the study cohort was comprised of 724 unique patients who underwent 791 therapeutic CAR-T infusions. A single case of a T-cell lymphoma positive for Epstein-Barr virus was identified in a 59-year-old woman previously treated with CAR T-cell therapy (axicabtagene ciloleuce…

Reviewing Author

Michael E. Williams, MD, ScM

Disclosures

Consultant/Advisory BoardAbbVie; AstraZeneca; Beigene; Janssen; Pharmacyclics

Grant/Research SupportJanssen

Editorial BoardsAmerican Board of Internal Medicine (ABIM) Hematology Longitudinal Knowledge Approval Committee

Michael E. Williams, MD, ScM

Disclosures

Consultant/Advisory BoardAbbVie; AstraZeneca; Beigene; Janssen; Pharmacyclics

Grant/Research SupportJanssen

Editorial BoardsAmerican Board of Internal Medicine (ABIM) Hematology Longitudinal Knowledge Approval Committee

T-Cell Lymphoma Following CAR T-Cell Therapy

Topics

Reviewing Author